Ligand Pharmaceuticals (NASDAQ: LGND)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Ligand Pharmaceuticals Return vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Ligand Pharmaceuticals Company Info
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
News & Analysis
The drugmaker is also looking for its highest sales ever in 2021 in large part because of remdesivir.
The Reddit crowd wasn't the only reason short-sellers got burned betting against this pharmaceutical company.
The unusual biotech could be a bitter pill for short sellers to swallow.
Should investors watch for a squeeze?
The company posted strong revenue and earnings growth in Q2 and upped its full-year outlook.
In the high-risk world of biotech investing, there are no guarantees of success. Still, sometimes investors can find places where the odds look reasonable enough to consider buying shares.
Investors are not impressed with the company's plan to finance an acquisition spree.
When Citron speaks, investors listen -- but should they?
LGND earnings call for the period ending September 30, 2021.
LGND earnings call for the period ending June 30, 2021.
LGND earnings call for the period ending March 31, 2021.
LGND earnings call for the period ending December 31, 2020.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.